AbbVie Reports Third-Quarter 2023 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
AbbVie (ABBV) shares dip as revenue drops 6% from last year
October 27, 2023 9:58 AM EDTAbbVie (NYSE: ABBV) shares dipped at the open Friday despite reporting its latest quarterly earnings that beat consensus expectations.
The pharmaceutical firm reported Q3 EPS of $2.95, $0.08 better than the analyst estimate of $2.87, while revenue for the quarter came in at $13.93 billion versus the consensus estimate of $13.71 billion.
The company's revenue dipped 6% from a year ago. Revenues from its immunology portfolio fell 11.3%, while its oncology segment... More
AbbVie (ABBV) Tops Q3 EPS by 8c, Offers Guidance
October 27, 2023 7:40 AM EDTAbbVie (NYSE: ABBV) reported Q3 EPS of $2.95, $0.08 better than the analyst estimate of $2.87. Revenue for the quarter came in at $13.93 billion versus the consensus estimate of $13.71 billion.
GUIDANCE:
AbbVie sees Q4 2023 EPS of $11.19-$11.23, versus the consensus of $11.06.
For earnings history and earnings-related data on AbbVie (ABBV) click here.
... More